Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Accumulated Expenses: 2022-2024

Historic Accumulated Expenses for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Dec 2024 value amounting to $8.7 million.

  • NewAmsterdam Pharma Co N.V's Accumulated Expenses rose 40.16% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year increase of 40.16%. This contributed to the annual value of $8.7 million for FY2024, which is 157.71% up from last year.
  • NewAmsterdam Pharma Co N.V's Accumulated Expenses amounted to $8.7 million in FY2024, which was up 157.71% from $3.4 million recorded in FY2023.
  • In the past 5 years, NewAmsterdam Pharma Co N.V's Accumulated Expenses ranged from a high of $8.7 million in FY2024 and a low of $2.0 million during FY2022.
  • In the last 3 years, NewAmsterdam Pharma Co N.V's Accumulated Expenses had a median value of $3.4 million in 2023 and averaged $4.7 million.
  • Data for NewAmsterdam Pharma Co N.V's Accumulated Expenses shows a peak YoY skyrocketed of 157.71% (in 2024) over the last 5 years.
  • Over the past 3 years, NewAmsterdam Pharma Co N.V's Accumulated Expenses (Yearly) stood at $2.0 million in 2022, then spiked by 69.37% to $3.4 million in 2023, then skyrocketed by 157.71% to $8.7 million in 2024.